Clinical efficacy and safety of using calcipotriol–betamethasone compounding agent for psoriasis treatment: a systematic review and meta-analysis
Authors:
- 20 August 2021
- journal article
- review article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 314 (7) , 633-641
Abstract
The main objective is to evaluate clinical efficacy and safety of using calcipotriol–betamethasone compounding agent for psoriasis treatment through a systematic review and meta-analysis. We searched MEDLINE, Embase, The Cochrane Library, China National Knowledge Infrastructure (CNKI), China Biomedical Literature Database (CBM), and WanFang Data from inception till July 31, 2020. Efficacy was evaluated based on primary outcome indicators including skin lesion improvement and overall adverse reaction rate. Secondary outcome indicators included degree of life quality improvement, clinical effectiveness rate, and specific adverse reaction rates. RevMan5.3 was used to perform the meta-analysis. 22 studies finally met our inclusion criteria for the meta-analysis. The results indicated that for short-term treatment, a sequential therapy that uses calcipotriol betamethasone compounding agent and calcipotriol improves PASI score (MD = −0.94, 95% CI − 1.38 ~ − 0.49, P < 0.0001, I2 = 49%), comparing with using only calcipotriol. From a drug safety perspective, the difference in overall adverse reaction rate is not significant between the calcipotriol group and the sequential treatment group (RR = 0.50, 95% CI 0.22 ~ 1.14, P = 0.10, I2 = 33%). Calcipotriol betamethasone compounding agent may be more effective in plaque psoriasis treatment compared to use only calcipotriol, with no significant difference in adverse reaction rate between the two groups. Although the data were collected from 13 comparison groups, each group may not have sufficient data for a thorough and comprehensive analysis. Further research may be necessary for a more detailed evaluation of effectiveness of using calcipotriol betamethasone compounding agent for plaque psoriasis treatment.Keywords
Funding Information
- Tianjin Municipal Health and health committee (ZC20114)
This publication has 33 references indexed in Scilit:
- Mechanisms of Action of Topical Corticosteroids in PsoriasisInternational Journal of Endocrinology, 2012
- Calcipotriol Induces Autophagy in HeLa Cells and KeratinocytesJournal of Investigative Dermatology, 2011
- The effectiveness of two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of moderately severe scalp psoriasis: A systematic review of direct and indirect evidenceCurrent Medical Research and Opinion, 2010
- Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgarisCurrent Medical Research and Opinion, 2010
- Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointmentInternational Journal of Dermatology, 2006
- Calcipotriol/betamethasone dipropionate for the treatment of psoriasisExpert Opinion on Pharmacotherapy, 2006
- A Two-Compound Product Containing Calcipotriol and Betamethasone Dipropionate Provides Rapid, Effective Treatment of Psoriasis vulgaris regardless of Baseline Disease SeverityDermatology, 2005
- The Topical Treatment of PsoriasisSkin Pharmacology and Physiology, 2003
- Topical calcipotriene has no short-term effect on calcium and bone metabolism of patients with psoriasisJournal of the American Academy of Dermatology, 1996
- Topically applied low-dose calcitriol has no calciotropic effect in patients with stable plaque psoriasisJournal of the American Academy of Dermatology, 1994